http://austinpublishinggroup.com/austin-hepatology/currentissue.php
Mannaerts et al.
recently reported that the effect or protein, Yap of the Hippo pathway
regulates liver fibrosis by controlling the activation of hepatic stellate
cells. The authors elegantly demonstrate that Yap activation induces fibrotic
phenotype using in vitro as well as in vivo models. Besides contributing to
liver failure, cirrhosis an advanced stage of fibrosis is known to be a major
underlying disease of primary liver cancer, Hepatocellular Carcinoma (HCC).
Thus experimental characterization of Yap’s role in fibrogenesis is clinically
relevant due to the necessity for a viable antifibrotic therapy.
Emerging
data show that Yap and hippo pathway in general are involved in liver
enlargement and the associated clonal expansion of HCC. Yet, detailed
mechanistic insights on the molecular regulation of fibrogenesis by Yap remain
unclear. Recent reports document that energy producing pathways are altered in
early/late cirrhotic stages and selective deregulation/ disruption of such
metabolic alteration block fibrotic phenotype in vitro and in vivo.Thus,
accumulating data indicate that metabolic alteration is indispensable for the
progression of fibrosis/ cirrhosis.
Corroborating this, Yap
and Hippo signaling mechanism have also been found to be regulated by energy
stress. Importantly, glucose-mediated energy homeostasis has been shown to
regulate Hippo pathway which in turn affects pro-glycolytic function of Yap.
Multiple lines of evidence have established that metabolism-related oxidative
stress is a major facilitator of fibrosis. Intriguingly, evidences also show
that Yap- Hippo pathway is affected by oxidative stress. Taken together, it is
thus far evident that cellular stress contributes for fibrogenesis and
Yap-Hippo pathway is affected by such cellular stress during fibrogenesis.
Future investigations focusing on molecular intricacies of Yap regulation by
metabolic stress will be critical and relevant to identify potential
therapeutic target (s) and development of any viable and translatable strategy
to treat liver fibrosis/cirrhosis.
No comments:
Post a Comment